A phase 1 dose escalation study of lapatinib and paclitaxel in recurrent ovarian cancer

被引：0
|
作者：
Cao, Connie D.
McCorkle, Joseph R.
Yan, Donglin
Jayswal, Rani
Miller, Rachel W.
Dietrich, Charles S.
Ueland, Frederick R.
Kolesar, Jill M.
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 05期
关键词：
D O I：
10.1158/1538-7445.OVARIAN23-B021
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B021
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Biweekly docetaxel in recurrent ovarian cancer: a phase I dose finding study
    Johanna Mäenpää
    Arto Leminen
    Cancer Chemotherapy and Pharmacology, 2009, 64 : 297 - 300
  • [22] Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer
    McCorkle, J. Robert
    Gorski, Justin W.
    Liu, Jinpeng
    Riggs, McKayla B.
    McDowell, Anthony B.
    Lin, Nan
    Wang, Chi
    Ueland, Frederick R.
    Kolesar, Jill M.
    PLOS ONE, 2021, 16 (08):
  • [23] Phase II study of gemcitabine and weekly paclitaxel in recurrent platinum-resistant ovarian cancer
    Garcia, AA
    O'Meara, A
    Bahador, A
    Facio, G
    Jeffers, S
    Kim, DY
    Roman, L
    GYNECOLOGIC ONCOLOGY, 2004, 93 (02) : 493 - 498
  • [24] Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer
    D'Agostino, G
    Amant, F
    Berteloot, P
    Scambia, G
    Vergote, I
    GYNECOLOGIC ONCOLOGY, 2003, 88 (03) : 266 - 269
  • [25] Phase I dose escalation study of gemcitabine and paclitaxel plus colony-stimulating factors in previously treated patients with advanced breast and ovarian cancer
    Iaffaioli, RV
    Tortoriello, A
    Santangelo, M
    Turitto, G
    Libutti, M
    Benassai, G
    Frattolillo, A
    Ciccarelli, PD
    De Rosa, P
    Crovella, F
    Carbone, I
    Barbarisi, A
    CLINICAL ONCOLOGY, 2000, 12 (04) : 251 - 255
  • [26] Paclitaxel in recurrent ovarian cancer: Better upfront? Comments on: A phase II study of paclitaxel in platinum pretreated ovarian cancer. A Hellenic Cooperative Oncology Group Study.
    Bulusu, VR
    EUROPEAN JOURNAL OF CANCER, 1997, 33 (11) : 1905 - 1906
  • [27] Dose-escalation phase I study in metastatic breast cancer patients with combination of paclitaxel and tegafur uracil
    Osaki, Akihiko
    Mitsuyama, Shoshu
    Kurebayashi, Jun-Ichi
    Sonoo, Hiroshi
    Nishimura, Reiki
    Koga, Toshihiro
    Murakami, Shigeru
    Ohno, Shinji
    ONCOLOGY LETTERS, 2010, 1 (01) : 45 - 49
  • [28] Dose escalation and pharmacokinetic study of irinotecan in combination with paclitaxel in patients with advanced cancer
    John R. Murren
    Kathleen Peccerillo
    Susan A. DiStasio
    Xin Li
    Janine J. Leffert
    Giuseppe Pizzorno
    Barbara A. Burtness
    Anne McKeon
    Yung chi Cheng
    Cancer Chemotherapy and Pharmacology, 2000, 46 : 43 - 50
  • [29] Dose escalation and pharmacokinetic study of irinotecan in combination with paclitaxel in patients with advanced cancer
    Murren, JR
    Peccerillo, K
    DiStasio, SA
    Li, X
    Leffert, JJ
    Pizzorno, G
    Burtness, BA
    McKeon, A
    Cheng, YC
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2000, 46 (01) : 43 - 50
  • [30] Dose-escalation study of weekly 1-hour paclitaxel administration in patients with refractory cancer
    Chang, AY
    Boros, L
    Asbury, R
    Hui, LF
    Rubins, J
    SEMINARS IN ONCOLOGY, 1997, 24 (05) : 69 - 71
12345